This randomized, multicentre, parallel-group study assessed the efficacy of epoetin beta in reducing the transfusion frequency in patients ineligible for autologous blood donation prior to surgery. The patients (n = 194) received either epoetin beta (125 or 250 IU/kg, once weekly) or no therapy for 3-4 weeks before surgery. The pre-operation haemoglobin levels were markedly increased in the epoetin beta groups (125 IU/kg: +1.1 g/dl; 250 IU/kg: +1.6 g/dl), but not in the control group. The transfusion frequency was significantly reduced in both epoetin groups as compared with the control group (p = 0.046). Epoetin beta was well tolerated, and no serious adverse events were observed. Low-dose administration of epoetin beta before elective surgery reduces the transfusion frequencies in patients not eligible for autologous blood donation.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000049723DOI Listing

Publication Analysis

Top Keywords

epoetin beta
24
autologous blood
12
blood donation
12
elective surgery
8
eligible autologous
8
transfusion frequency
8
250 iu/kg
8
control group
8
epoetin
7
beta
6

Similar Publications

Article Synopsis
  • The study investigates the effectiveness and safety of using vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, as an alternative to the erythropoiesis-stimulating agent methoxy polyethylene glycol-epoetin beta (MPG-EPO) in treating anemia for patients with chronic kidney disease (CKD) who are on dialysis.
  • This Phase 3b trial involved 456 adult participants, randomized into three groups receiving either vadadustat (at two different doses) or MPG-EPO, for up to 52 weeks, with a focus on changes in hemoglobin levels.
  • Results showed that vadadustat was noninferior to MPG-EPO regarding hemoglobin change
View Article and Find Full Text PDF

Objective Roxadustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, increases the hemoglobin (Hb) levels in patients with chronic kidney disease (CKD). To date, limited clinical studies have focused on the excessive increase in the Hb levels in the early weeks after switching from erythropoiesis-stimulating agents (ESA) to roxadustat in adult non-dialysis patients. We conducted a retrospective study to examine whether early overshoot frequently occurs after switching to roxadustat.

View Article and Find Full Text PDF

Erythropoiesis-stimulating agents (ESAs) continue to be a significant threat to the integrity of human and equine sports. Besides conventional direct testing, monitoring the biomarkers associated with the effects of ESAs may provide a complementary approach via indirect detection to enhance doping control. In this study, we applied label-free proteomics to discover plasma protein biomarkers in Thoroughbred geldings after administration with a long-acting form of recombinant human erythropoietin (rhEPO), methoxy polyethylene glycol epoetin beta, Mircera.

View Article and Find Full Text PDF

A number of drugs based on recombinant erythropoietin contain human serum albumin as an auxiliary component. The presence of this protein hinders the proper control of the drug quality in accordance with the requirements of regulating agencies. We propose the novel method for separation of recombinant erythropoietin (epoetin beta) and human serum albumin.

View Article and Find Full Text PDF

An improved screening workflow and a robust capillary flow LC-MS confirmatory method for the detection of recombinant human erythropoietin (rHuEPO) has been implemented to increase the sensitivity of rHuEPO detection and to reduce the number of suspect samples committed to confirmatory testing. The influence of repeated dosing of epoetin-β on the detection window of rHuEPO in equine plasma was assessed using the optimised method. Samples were initially assessed using an economical R&D Human EPO Duo-Set ELISA Development System.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!